This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
LZIC / Protein LZIC · IHC design guide
Design Immunohistochemistry for LZIC
Plan LZIC staining in paraffin sections using the reported nuclear tissue pattern (HPA tissue IHC). The catalog antibody A15087 has an IHC dilution of 2–5 μg/ml (datasheet A15087); kidney tubules provide a reported staining reference (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
LZIC Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear staining in several tissues (HPA tissue IHC) | |
| Staining pattern | Nuclear staining in glandular cells in several tissues (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A15087) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A15087) | |
| Caveat | Staining has medium consistency with RNA expression (HPA tissue IHC) | |
| Regulation | Up-regulated in some gastric cancers (UniProt) | |
| Isoform / epitope | 2 isoforms; epitope coverage is unspecified (UniProt) |
Section 1
Recommended LZIC IHC & IF Protocols
The catalog antibody’s IHC-P protocol uses EDTA retrieval (datasheet: A15087). One published protocol stains human brain sections (PMC13183923).
| Sample | Paraffin-embedded human prostatic cancer tissue; fixative not specified (datasheet A15087) |
| Fixation | Image fixative and duration unreported (datasheet A15087); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A15087); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A15087) |
| Primary antibody | Rabbit anti-LZIC, 2-5 μg/ml (datasheet A15087) |
| Primary incubation | Overnight at 4 °C (datasheet A15087) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A15087) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | LZIC-positive staining in glandular cells of adrenal gland (HPA tissue IHC: Medium). HPA tissue profile: Nuclear expression in several tissues. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 heat-mediated retrieval for the catalog antibody (datasheet: A15087). The published protocol used high-pressure citrate pH 6.0 (PMC13183923).
Section 2
What Is the Expected LZIC Staining Pattern?
LZIC is expected mainly in nuclei across several tissues (HPA tissue IHC: nuclear profile). Kidney tubule cells and glandular cells in the colon, duodenum, adrenal gland, endometrium, epididymis and gallbladder show medium staining (HPA tissue IHC). HPA rates the tissue IHC profile Approved, with medium consistency against RNA data and external verification pending (HPA tissue IHC). LZIC has no annotated transmembrane segment (UniProt Q8WZA0 topology).
| Nuclear staining in kidney tubule cells or the listed glandular cells, at about the reference intensity. | This fits the reported nuclear tissue profile and medium staining in those cells (HPA tissue IHC). Compare cells within the same section before scoring: a tissue-level label does not mean every cell is equally positive. |
| Strong staining confined to an unexpected compartment, with little nuclear signal. | Treat the IHC pattern as questionable against the nuclear tissue profile (HPA tissue IHC). Cytosolic localization is also approved in ICC-IF (HPA subcellular), so cytoplasmic signal alone cannot prove an artefact; check controls and morphology. |
| Prominent staining in adipocytes or bone marrow hematopoietic cells. | Those cell types are reported as not detected (HPA tissue IHC). Consider antibody cross-reactivity or endogenous detection activity (general IHC practice), especially if the signal persists in a no-primary control. |
| Diffuse colour across tissue, including spaces outside recognizable cells. | This does not resemble the reported nuclear expression profile (HPA tissue IHC). Uneven blocking, excess detection reagent or chromogen development can create background (general IHC practice); interpret cell-specific staining only after controls are clean. |
| No signal in kidney tubule cells despite intact tissue and visible counterstain. | Kidney tubule cells show medium staining in the HPA reference (HPA tissue IHC). First check the run and antibody conditions (general IHC practice); a single negative slide does not establish that LZIC is absent. |
💡Expected LZIC appearanceCall a positive IHC result when recognizable nuclei in kidney tubule or listed glandular cells show medium staining (HPA tissue IHC); widespread colour in negative-reference cells or outside cells is suspect (HPA tissue IHC; general IHC practice).
| Tissue and cell choice | Kidney tubule cells and several glandular cell populations are medium-staining references; adipocytes and bone marrow hematopoietic cells are not detected (HPA tissue IHC). Use the reported cell population, not the whole organ, for comparison. |
| Antibody evidence | HPA028184 has Approved IHC status (HPA antibodies). The overall tissue profile has medium agreement with RNA data and awaits external verification (HPA tissue IHC); match the observed cell pattern before assigning specificity. |
| Isoforms and processing | UniProt lists two LZIC isoforms, one chain spanning residues 1–190, no signal peptide and no propeptide (UniProt Q8WZA0). The supplied evidence does not identify which isoform an IHC stain detects. |
| Topology and modifications | No transmembrane segment, glycosylation site or modified residue is annotated (UniProt Q8WZA0). These annotations do not locate an antibody epitope or predict antigen retrieval performance. |
| IF/ICC Q&A: should fluorescence be nuclear only? | No. Nucleoplasm is the approved main location, with cytosol also approved, in ICC-IF images from SK-MEL-30 and U2OS (HPA subcellular). This is a localization reference, not an IHC protocol or evidence for every tissue. |
| Situation | Likely cause | Next action |
|---|---|---|
| Kidney tubule cells are blank. | The reference shows medium staining there (HPA tissue IHC); the cause in this run is undetermined. | Check reagent identity, dilution and expiry; confirm retrieval and detection steps with run controls (general IHC practice). Do not assign target-specific fixation sensitivity from this result. |
| Most cells show uniform brown haze. | Diffuse colour conflicts with the nuclear tissue profile (HPA tissue IHC); nonspecific reagent binding or excess development is possible (general IHC practice). | Review the no-primary control, blocking, washes and chromogen development; then repeat with controlled detection conditions (general IHC practice). |
| Negative-reference cells stain strongly. | Adipocytes or bone marrow hematopoietic cells are not detected in the reference (HPA tissue IHC); cross-reactivity or endogenous detection activity is possible (general IHC practice). | Compare a no-primary control and the positive-reference cells on the same run; resolve background before scoring those cells as LZIC-positive (general IHC practice). |
| Signal is mainly cytoplasmic in an IHC section. | The tissue IHC profile is nuclear (HPA tissue IHC), although cytosol is an approved additional ICC-IF location (HPA subcellular). | Check nuclear counterstain, tissue morphology and controls. Record compartment-specific staining separately; avoid calling cytoplasmic signal definitive without corroboration. |
| A whole section is called negative because one cell type is blank. | HPA reports staining by cell type: appendix glandular cells are not detected, while colon glandular cells are medium (HPA tissue IHC). | Score named cell populations separately and include a reported positive-reference population when comparing runs (HPA tissue IHC; general IHC practice). |
| IF/ICC shows both nuclear and cytosolic fluorescence. | Nucleoplasm is the approved main site and cytosol an approved additional site in ICC-IF (HPA subcellular). | Evaluate whether both signals follow cell boundaries and survive appropriate fluorescence controls (general IF practice); do not use this observation as an IHC protocol choice. |
Experiment evidence
IHC & IF images showing LZIC staining
A15087 · IHCIHC analysis of LZIC using anti-LZIC antibody (A15087). LZIC was detected in a paraffin-embedded section of human prostatic cancer tissue. H
A15087 · IHCIHC analysis of LZIC using anti-LZIC antibody (A15087). LZIC was detected in a paraffin-embedded section of mouse brain tissue. Heat mediate
A15087 · IFIF analysis of LZIC using anti-LZIC antibody (A15087) and anti-Beta Tubulin antibody (M01857-3). LZIC was detected in immunocytochemical sec
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000162441-LZIC/tissue/cerebral+cortex#imid_7072760
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000162441-LZIC/tissue/colon#imid_7072686
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000162441-LZIC/tissue/liver#imid_7072687
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000162441-LZIC/tissue/kidney#imid_7072688
HPA · ICC-IF SK-MEL-30Human Protein Atlas immunofluorescence, SK-MEL-30, antibody HPA058614; green = LZIC, blue = nucleus, red = microtubules.
HPA · ICC-IF SK-MEL-30Human Protein Atlas immunofluorescence, SK-MEL-30, antibody HPA058614; green = LZIC, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for LZIC IHC & IF
🧪Run adrenal gland first: its glandular cells should stain (HPA: adrenal glandular cells, Medium). Run adipose tissue as a negative comparator (HPA: adipocytes, Not detected); no specific internal negative cell type is established for the adrenal slide, so assess apparently unstained cells as background comparators without assuming they lack LZIC (HPA: adrenal glandular cells, Medium).
Positive control tissue: Adrenal gland (Glandular cells, HPA Medium)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show LZIC in SK-MEL-30, U2OS, with annotated localisation: Nucleoplasm (approved) (HPA subcellular).
Technical controls: Include no-primary (secondary-only) and host-matched rabbit isotype controls (caption: rabbit anti-LZIC antibody); use an LZIC knockout specimen, if available, as a biological negative (standard IHC practice). Block endogenous peroxidase before HRP/DAB detection, and check the adrenal slide for endogenous brown pigment that could resemble DAB signal (caption: HRP/DAB detection; standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A15087 paraffin-section caption does not state the fixative (caption: fixative not stated). The caption uses heat retrieval in EDTA at pH 8.0, but does not establish whether retrieval is required (caption: EDTA retrieval, pH 8.0). The supplied evidence does not show that frozen sections or IF would be easier; endogenous adrenal pigment may complicate interpretation of brown DAB staining (caption: DAB detection; standard IHC practice).
HPA tissue IHC evidence for LZIC
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Medium consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
| Cerebral cortex | Neuropil | Medium | Protein (IHC) | HPA → |
| Colon | Glandular cells | Medium | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | Medium | Protein (IHC) | HPA → |
| Endometrium | Glandular cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Caudate | Glial cells | Not detected | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced LZIC IHC Tips
Use the A15087 paraffin-section conditions as a starting point, then assess compartment-specific staining against tissue controls and the available LZIC localisation evidence.
Which retrieval condition should I start with for LZIC paraffin IHC?
Start with heat-mediated retrieval in EDTA pH 8.0 for paraffin-section LZIC IHC (datasheet A15087). The reported prostatic cancer section used that condition before incubation with 2 μg/ml primary antibody overnight at 4°C (datasheet A15087). If staining is weak, compare a shorter and longer heating interval on matched sections while keeping buffer, antibody concentration and detection constant (standard IHC practice). Include a kidney section with tubule cells as a reference for detectable staining, alongside a primary-antibody omission control (HPA tissue IHC: kidney tubule cells Medium; standard IHC practice). Avoid judging retrieval from DAB intensity alone; check whether cell outlines and nuclear detail remain intact (standard IHC practice).
How should I troubleshoot fixation-dependent loss of LZIC staining?
The A15087 image documents a paraffin-embedded section but does not state its fixative, so LZIC-specific fixation sensitivity is unknown (datasheet A15087). For a validation series, process matched samples with the laboratory’s routine 10% neutral buffered formalin workflow and record fixation duration before comparing staining (standard IHC practice). Keep section thickness, EDTA pH 8.0 retrieval and DAB development consistent across that series (datasheet A15087; standard IHC practice). Interpret a weak result only after checking preserved morphology, a positive reference section and a primary-antibody omission control (standard IHC practice). Neither tissue staining patterns nor the absence of a transmembrane segment establishes how LZIC responds to fixation (HPA tissue IHC; UniProt Q8WZA0 topology).
Should LZIC stain nuclei or cytoplasm in tissue sections?
Expect to evaluate nuclear staining first: tissue IHC reports nuclear expression in several tissues, while ICC/IF places LZIC mainly in the nucleoplasm with additional cytosolic localisation (HPA tissue IHC; HPA subcellular). Score nuclear and cytoplasmic signals separately in each annotated cell population rather than treating all brown material as one compartment (standard IHC practice). In kidney, examine tubule cells, where staining is reported at a Medium level, and compare surrounding compartments on the same section (HPA tissue IHC: kidney tubule cells Medium). A cytoplasmic-only result warrants review of retrieval, counterstain and background controls before assignment to LZIC; the record provides no transmembrane segment or annotated UniProt compartment (UniProt Q8WZA0 topology and subcellular record).
Can this IHC assay distinguish the two LZIC isoforms?
Do not assign an isoform from staining unless the antibody’s epitope is mapped to sequence unique to that isoform and the distinction is validated in sections (standard IHC practice). UniProt lists 2 LZIC isoforms but supplies no epitope map for A15087 in this payload (UniProt Q8WZA0 isoforms; datasheet A15087). Ask for the immunogen sequence or mapped epitope, then compare it against both isoform sequences before designing an isoform-specific interpretation (standard IHC practice). Retrieval can change epitope accessibility, so hold EDTA pH 8.0 constant during that comparison (datasheet A15087; standard IHC practice). The record lists no glycosylation sites or modified residues; these annotations do not establish antibody specificity (UniProt Q8WZA0).
How can I investigate LZIC localisation by IF alongside tissue IHC?
Treat IF/ICC as a separate assay: HPA provides ICC/IF images in SK-MEL-30 and U2OS and reports mainly nucleoplasmic, with additional cytosolic, LZIC localisation (HPA subcellular). For tissue multiplexing, pair LZIC with a validated marker of the cell population being scored, such as a tubule-cell marker when examining kidney (HPA tissue IHC: kidney tubule cells Medium; standard IF practice). Choose fluorophores after viewing unstained tissue channels, placing the weaker signal in a channel with lower autofluorescence (standard IF practice). LZIC has no annotated transmembrane segment and its antibody epitope is unspecified; compare gentle detergent permeabilisation conditions that permit nucleoplasmic and cytosolic access without assuming a membrane-facing epitope (UniProt Q8WZA0 topology; HPA subcellular; standard IF practice).
What should I change when LZIC DAB staining looks diffuse?
First compare a primary-antibody omission section with the stained section to separate detection-system colour from antibody-dependent signal (standard IHC practice). The A15087 paraffin-section example used 10% goat serum blocking, 2 μg/ml primary overnight at 4°C, and peroxidase-based DAB detection (datasheet A15087). Apply a peroxidase block before detection, then titrate the primary concentration and DAB development time on matched sections if background persists (standard chromogenic IHC practice). Inspect tissue folds, section edges and pigment under the counterstain before calling diffuse colour cytosolic LZIC (standard IHC practice). Cytosolic localisation is reported in ICC/IF, but that observation alone cannot identify diffuse tissue DAB as specific staining (HPA subcellular).
How should I quantify LZIC staining across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and compartment before scoring; for kidney, HPA reports Medium staining in tubule cells, while its tissue profile describes nuclear expression in several tissues (HPA tissue IHC). For chromogenic sections, record the percentage of positive nuclei and intensity from 0–3, then calculate an H-score from 0–300 within the defined population (standard IHC scoring practice). If cell abundance varies, report positive cells per mm² of viable annotated tissue or normalise positive nuclei to all scored nuclei (standard IHC scoring practice). Use identical retrieval, exposure-free brightfield acquisition and DAB development settings across the comparison, and retain separate cytoplasmic scores if that signal is assessed (standard IHC practice; datasheet A15087 retrieval).
How do I distinguish true LZIC staining from artefact?
Give greatest weight to reproducible nuclear staining in intact cells: HPA reports nuclear tissue expression and mainly nucleoplasmic ICC/IF localisation, with additional cytosolic signal (HPA tissue IHC; HPA subcellular). Check the cell identity against the compartment being examined; kidney tubule cells have reported Medium staining, whereas appendix glandular cells are reported Not detected (HPA tissue IHC). Review edge-only colour, necrotic areas, folds and residual endogenous peroxidase signal against adjacent morphology and a primary-antibody omission control (standard chromogenic IHC practice). A strong brown deposit in a mismatched compartment or only in damaged regions needs independent validation before attribution to LZIC (standard IHC interpretation; HPA subcellular). HPA rates tissue IHC Approved with medium RNA concordance and pending external verification (HPA tissue IHC).
Boster reagents
Best LZIC / Protein LZIC IHC Antibodies
A15087 has IHC images from paraffin sections of human prostatic cancer and mouse and rat brain, plus IF data from human A549 cells (catalog image captions).
Real IHC data
Anti-LZIC Antibody ®
Cat # A15087
A15087 is listed for IHC in human, mouse and rat, with images from paraffin sections of human prostatic cancer and mouse and rat brain (catalog applications; catalog IHC captions). A15087 is also listed for IF/ICC, with an IF image from human A549 cells (catalog applications; catalog IF caption).
Which to pick: For paraffin-section IHC, choose A15087: its images use heat retrieval in EDTA at pH 8.0 and 2 μg/ml primary antibody, within the listed 2–5 μg/ml IHC range (A15087 IHC captions; catalog dilution). For IF/ICC, A15087 has a human A549 IF image at 5 μg/ml; for cross-species IHC, its images cover human, mouse and rat sections (A15087 IF caption; A15087 IHC captions). The antibody is rabbit-hosted, its clonality is unreported, and the IHC captions do not report a fixative (catalog host; catalog IHC captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q8WZA0 (LZIC_HUMAN, Protein LZIC).
- Human Protein Atlas. LZIC tissue IHC expression (reliability: Approved).
- Human Protein Atlas. LZIC subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the cytosol..
- Human Protein Atlas. LZIC antibody validation summary (2 antibodies).
- A comparative analysis of serum and tissue proteomic profiles in non-small cell lung cancer patients with or without brain metastasis. Cell death discovery 2026 — PMC13183923.
- PubMed PMID:11712074 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:16710414 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for LZIC (Protein LZIC). Expected localisation Nuclear staining in several tissues (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A15087). Validated IHC antibody: A15087 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human prostatic cancer tissue; fixative not specified (datasheet A15087); 2. Fixation: Image fixative and duration unreported (datasheet A15087); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A15087); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A15087); 8. Primary antibody: Rabbit anti-LZIC, 2-5 μg/ml (datasheet A15087); 9. Primary incubation: Overnight at 4 °C (datasheet A15087). Watch for: Fixation: Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A15087); Caveat: Staining has medium consistency with RNA expression (HPA tissue IHC); Isoform / epitope: 2 isoforms; epitope coverage is unspecified (UniProt); Regulation: Up-regulated in some gastric cancers (UniProt). Evidence: UniProt Q8WZA0, HPA tissue IHC · Approved, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to the…, Datasheet A15087, PMC13183923. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/LZIC/immunohistochemistry-ihc-guide.